Streetbeat News

GHRS

GH Research PLC

https://www.ghres.com

Industry

Biotechnology

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Open

10.39

Mkt cap

628M

Volume

219K

High

10.67

P/E Ratio

-13.51

52-wk high

20.50

Low

10.08

Div yield

N/A

52-wk low

6.00

GH Research PLC (Nasdaq: GHRS) reported its full-year 2024 financial results and provided business updates. The company is progressing with its Phase 2b trial of GH001 for treatment-resistant depression, aiming for completion in Q1 2025. A Phase 1 trial for an aerosol delivery device is ongoing, and a response to an IND hold is expected by mid-2025. GHRS has $182.6 million in cash and received $139.8 million from a public offering in February 2025.

Portfolio Pulse from

February 27, 2025 | 12:15 pm

GH Research stock (GHRS) surged 55% in a week following successful results from a mid-stage depression study of its lead candidate, GH001.

Portfolio Pulse from

February 06, 2025 | 4:45 pm

GH Research PLC has announced the pricing of its public offering of 10 million ordinary shares at $15 each, aiming to raise $150 million. The offering is expected to close on February 6, 2025, with an option for underwriters to purchase an additional 1.5 million shares.

Portfolio Pulse from

February 05, 2025 | 2:00 am

GH Research PLC (Nasdaq: GHRS) announced a proposed public offering of $150 million in ordinary shares, with an option for underwriters to purchase an additional $22.5 million. The offering's completion is subject to market conditions.

Portfolio Pulse from

February 03, 2025 | 9:15 pm

GH Research PLC announced that their Phase 2b trial for GH001, an inhalable treatment for treatment-resistant depression, met its primary endpoint with a significant placebo-adjusted reduction in depression scores.

Portfolio Pulse from

February 03, 2025 | 12:15 pm

GH Research PLC (Nasdaq: GHRS) will host a conference call on February 3, 2025, to update on their Phase 2b trial of GH001 for treatment-resistant depression.

Portfolio Pulse from

January 31, 2025 | 9:15 pm

GH Research PLC announced successful results from two Phase 2a trials with GH001, meeting primary endpoints. The company also completed all FDA requests regarding an IND hold, with no respiratory toxicity findings in non-rodents.

Portfolio Pulse from

January 10, 2025 | 12:15 pm

Analysts predict a potential 225.2% upside for GH Research (GHRS) stock, based on the mean of their price targets. Despite the metric's mixed reliability, consensus on raising earnings estimates suggests a positive outlook.

Portfolio Pulse from

November 20, 2024 | 4:00 pm

GH Research PLC, a clinical-stage biopharmaceutical company, reported its Q3 2024 financial results and provided business updates. The company is focused on transforming the treatment of psychiatric and neurological disorders.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.